Table 3

 Demographic, clinical, and biological data on six patients treated with rituximab for primary Sjögren’s syndrome

CaseSex/age/duration (y)Previous ISClinical involvement at beginning of rituximab treatmentNo of infusions × dose (mg)/No of MP pulses/concomitant ISAdverse event (Y/N)Efficacy on extraglandular involvement (Y/N)Initial/final VASEfficacy on objective dryness (Y/N)Time to response (w)/follow up (m)Prednisone initial/lastRF (IU/l) intial/last (n <20)Relapse (Y/N)/time to relapse (m)
AZA, azathioprine; CPH, cyclophosphamide; cryo, cryoglobulinaemia; ETA, etanercept; F, female; HQ, hydroxychloroquine; inflix, infliximab; IS, immunosuppressants; m, months; M, male; MALT, mucosa associated lymphoid tissue; MP, methylprednisolone; MTX, methotrexate; N, no; NA, not available; neg, negative; pos, positive; RF, rheumatoid factor (determined by nephelometry, except RF stated as “pos/neg”, determined by latex); VAS, visual analogical scale; w, weeks; y, years; Y, yes; –, not relevant.
28F/58/15HQDigestive lymphoma (MALT)4×375.m−2/4/MP (500)/HQNYDryness VAS: 80/50Stable Schirmer4/69/644/0N
29F/43/4NoSalivary lymphoma (MALT)4×375.m−2Serum sicknessNNANA–/110/0499/423
30F/71/5HQ/CPH/AZAVasculitis4×375.m−2NYNAStable Schirmer, salivary flow  = 08/815/7.5RF: 109/57 cryo: 1%/negN
31F/58/2CPHVasculitis4×375.m−2NYNANA8/810/0RF: 170/neg cryo: pos/negN
32F/74/18MTX/ETA/inflixParotid gland enlargement, polysynovitis4×375.m−2/4/MP (40)NYDryness VAS: 60/20NA4/76/6RF: 130/NAN
Fatigue VAS: 70/0
33F/41/8CPHParotid gland enlargement, polyarthralgia2×375.m−2/2/MP (40)Infusion relatedYDryness VAS: 20/0NA4/74/0NAN
Fatigue VAS: 80/0